Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.53M Sell
21,055
-1,028
-5% -$119K 0.8% 30
2025
Q4
$2.32M Sell
22,083
-232
-1% -$21.8K 0.75% 33
2025
Q3
$1.87M Buy
22,315
+4,513
+25% +$372K 0.63% 37
2025
Q2
$1.41M Buy
17,802
+2,364
+15% +$188K 0.54% 51
2025
Q1
$1.39M Buy
15,438
+1,275
+9% +$119K 0.58% 44
2024
Q4
$1.41M Buy
14,163
+2,579
+22% +$266K 0.61% 38
2024
Q3
$1.21M Buy
11,584
+401
+4% +$47.6K 0.53% 40
2024
Q2
$1.38M Buy
11,183
+97
+0.9% +$12.5K 0.67% 31
2024
Q1
$1.46M Buy
+11,086
New +$1.37M 0.73% 31

Other funds holding MRK

Gen-Wealth Partners's MRK Position: Q1 2026 in Review

Gen-Wealth Partners reduced its Merck (MRK) stake by 4.7% in Q1 2026, selling an estimated $119K and leaving 21,055 shares worth $2.53M. The position accounts for 0.8% of the portfolio, ranked #30.

Gen-Wealth Partners first reported a position in MRK in Q1 2024 and has held it in 9 quarters since. 3,788 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Gen-Wealth Partners held 21,055 shares of Merck worth $2.53M as of Q1 2026.
  • Gen-Wealth Partners sold 1,028 Merck shares in Q1 2026, an estimated $119K.
  • Merck made up 0.8% of Gen-Wealth Partners's portfolio in Q1 2026, its #30 holding.
  • Gen-Wealth Partners first reported a position in Merck in Q1 2024 and has held it in 9 quarters since.
  • 3,788 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Gen-Wealth Partners's 13F filing for Q1 2026, filed 8 May 2026.